Insider Selling: Cytokinetics (NASDAQ:CYTK) Director Sells $357,400.00 in Stock

Cytokinetics, Incorporated (NASDAQ:CYTK) Director B Lynne Parshall sold 5,000 shares of the company’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $71.48, for a total value of $357,400.00. Following the transaction, the director directly owned 10,784 shares in the company, valued at $770,840.32. The trade was a 31.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Cytokinetics Price Performance

Cytokinetics stock traded up $0.49 during mid-day trading on Tuesday, hitting $71.40. The company’s stock had a trading volume of 1,898,300 shares, compared to its average volume of 2,146,721. Cytokinetics, Incorporated has a 52-week low of $44.91 and a 52-week high of $88.31. The company has a market cap of $8.88 billion, a PE ratio of -9.89 and a beta of 0.39. The firm’s 50 day moving average is $79.95 and its 200 day moving average is $72.33.

Cytokinetics (NASDAQ:CYTK) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.50) earnings per share for the quarter, beating the consensus estimate of ($1.63) by $0.13. The business had revenue of $28.62 million for the quarter, compared to analysts’ expectations of $17.59 million. The company’s revenue was down 57.1% compared to the same quarter last year. During the same period last year, the firm earned ($1.12) EPS. As a group, analysts forecast that Cytokinetics, Incorporated will post -6 EPS for the current year.

Institutional Trading of Cytokinetics

Several large investors have recently added to or reduced their stakes in CYTK. EverSource Wealth Advisors LLC raised its holdings in shares of Cytokinetics by 723.7% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 766 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 673 shares in the last quarter. Kemnay Advisory Services Inc. bought a new stake in Cytokinetics in the fourth quarter worth $27,000. Kestra Advisory Services LLC bought a new stake in Cytokinetics in the fourth quarter worth $29,000. Quarry LP acquired a new position in Cytokinetics during the third quarter worth $30,000. Finally, Advisory Services Network LLC acquired a new position in Cytokinetics during the third quarter worth $32,000.

Cytokinetics News Roundup

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Cytokinetics reached a Phase 3 milestone in non-obstructive hypertrophic cardiomyopathy (HCM), highlighting progress for its cardiac-medicine pipeline and potentially expanding the company’s commercial opportunity. Cytokinetics Reaches a Phase 3 First in Non-Obstructive HCM
• Positive Sentiment: New Phase 3 data provided an additional catalyst for CYTK, reinforcing investor focus on clinical execution and the potential value of its late-stage drug candidates. The company is also viewed by one analysis as approximately 34% undervalued, although such valuation estimates are subjective. Cytokinetics Presents New Phase 3 Data
• Positive Sentiment: HC Wainwright reaffirmed its “buy” rating and set a $140 price target, substantially above recent trading levels. The broader analyst consensus remains “Moderate Buy,” with a reported average target of $102.20. HC Wainwright Reaffirms Cytokinetics Buy Rating
• Neutral Sentiment: CEO Robert Blum sold 7,500 shares and EVP Andrew Callos sold 10,000 shares at an average price of $70.24. Both transactions were executed under pre-arranged Rule 10b5-1 plans, reducing the signal that the sales reflect a new negative view of the business.
• Negative Sentiment: Wall Street Zen lowered its rating on Cytokinetics, creating a counterpoint to the predominantly bullish analyst coverage and potentially limiting near-term enthusiasm. Cytokinetics Stock Rating Lowered by Wall Street Zen

Analysts Set New Price Targets

CYTK has been the topic of several research reports. Royal Bank Of Canada dropped their price objective on shares of Cytokinetics from $117.00 to $112.00 and set an “outperform” rating on the stock in a research note on Friday, August 7th. JPMorgan Chase & Co. boosted their price target on shares of Cytokinetics from $97.00 to $103.00 and gave the company an “overweight” rating in a report on Thursday, August 13th. Wall Street Zen downgraded shares of Cytokinetics from a “hold” rating to a “sell” rating in a research note on Saturday. Barclays increased their price objective on Cytokinetics from $95.00 to $110.00 and gave the stock an “overweight” rating in a report on Thursday, August 13th. Finally, HC Wainwright reissued a “buy” rating and set a $140.00 price objective on shares of Cytokinetics in a research report on Monday. Nineteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Cytokinetics has a consensus rating of “Moderate Buy” and a consensus price target of $102.20.

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.